AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells

International Journal of Radiation Oncology Biology Physics

Volumn 84, Issue 4, 2012, Pages

  Raghavan, Pavithra ^a   Tumati, Vasu ^a   Yu, Lan ^a   Chan, Norman ^b   Tomimatsu, Nozomi ^a   Burma, Sandeep ^a,c   Bristow, Robert G ^b   Saha, Debabrata ^a,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ORGANS; CELL CULTURE; CELL DEATH; ENZYME INHIBITION; IONIZING RADIATION; REPAIR; TUMORS;

CYCLIN-DEPENDENT KINASE INHIBITORS; DNA DOUBLE STRAND BREAKS; HOMOLOGOUS RECOMBINATION; METHODS AND MATERIALS; NON SMALL CELL LUNG CANCER; NON-SMALL CELL LUNG CARCINOMATA; SPECIFIC INHIBITORS; SURVIVING FRACTIONS;

RADIOTHERAPY;

ATR PROTEIN; AZD 5438; AZD5438; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 9; CYCLIN DEPENDENT KINASE INHIBITOR; DOUBLE STRANDED DNA; RADIOSENSITIZING AGENT; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE; IMIDAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL SURVIVAL; CONTROLLED STUDY; DNA REPAIR; DRUG EFFICACY; DRUG POTENCY; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; RADIOSENSITIZATION; TREATMENT RESPONSE; TUMOR XENOGRAFT; ANIMAL; CELL CYCLE; DOUBLE STRANDED DNA BREAK; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; GENETICS; LUNG TUMOR; NUDE MOUSE; PATHOLOGY; RADIATION DOSE; RADIATION EXPOSURE; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CDC2 PROTEIN KINASE; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 9; CYCLIN-DEPENDENT KINASES; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; FEMALE; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; MICE; MICE, NUDE; PYRIMIDINES; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84872041276     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2012.05.035     Document Type: Article

References (19)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Jassem J. The role of radiotherapy in lung cancer: where is the evidence? Radiother Oncol 2007; 83: 203-213.
3. Sherr CJ. G1 phase progression: cycling on cue. Cell 1994; 79: 551-555.
4. Dickson MA, Schwartz GK. Development of cell-cycle inhibitors for cancer therapy. Curr Oncol 2009; 16: 36-43.
5. Manchado E, Guillamot M, Malumbres M. Killing cells by targeting mitosis. Cell Death Differ 2012; 19: 369-377.
6. Bible KC, Kaufmann SH. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res 1996; 56: 4856-4861.
7. Kim JC, Saha D, Cao Q, et al. Enhancement of radiation effects by combined docetaxel and flavopiridol treatment in lung cancer cells. Radiother Oncol 2004; 71: 213-221.
8. Kodym E, Kodym R, Reis AE, et al. The small-molecule Cdk inhibitor, SNS-032, enhances cellular radiosensitivity in quiescent and hypoxic non-small-cell lung cancer cells. Lung Cancer 2009; 37-47.
9. Byth KF, Thomas A, Hughes G, et al. AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmaco-dynamic changes and potent antitumor effects in human tumor xenografts. Mol Cancer Ther 2009; 8: 1856-1866.
10. Kong Z, Xie D, Boike T, et al. Downregulation of human DAB2IP gene expression in prostate cancer cells results in resistance to ionizing radiation. Cancer Res 2010; 70: 2829-2839.
11. Chan N, Koritzinsky M, Zhao H, et al. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemo-resistance and radioresistance. Cancer Res 2008; 68: 605-614.
12. Kong Z, Raghavan P, Xie D, et al. Epothilone B confers radiation dose enhancement in DAB2IP gene knock-down radioresistant prostate cancer cells. Int J Radiat Oncol Biol Phys 2010; 78: 1210-1218.
13. Ira G, Pellicioli A, Balijja A, et al. DNA end resection, homologous recombination and DNA damage checkpoint activation require CDK1. Nature 2004; 431: 1011-1017.
14. Johnson N, Li YC, Walton ZE, et al. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med 2011; 17: 875-882.
15. Peasland A, Wang LZ, Rowling E, et al. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. Br J Cancer 2011; 105: 372-381.
16. Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the anti-tumor effects of ionizing radiation. Cancer Res 1999; 59: 3374-3378.
17. Melillo G, Sausville EA, Cloud K, et al. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res 1999; 59: 5433-5437.
18. Castedo M, Perfettini JL, Roumier T, et al. Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe. Cell Death Differ 2002; 9: 1287-1293.
19. Boss DS, Schwartz GK, Middleton MR, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours. Ann Oncol 2010; 21: 884-894.